BlossomHill Stock Gains After Positive Lung Cancer Drug Trial Data

BlossomHill Therapeutics Inc. (NASDAQ:BLSM) shares climbed 4.4% in Tuesday premarket trading following the release of positive clinical data for its experimental lung cancer treatment, BH-30643. The company announced the drug demonstrated significant efficacy in patients with a specific type of treatment-resistant cancer, a development that could address a major unmet need in oncology.

Key Trial Results

The updated data from the ongoing Phase 1/2 SOLARA trial was presented at the International Association for the Study of Lung Cancer 2026 World Conference. The results focused on a cohort of 40 patients with EGFR C797S-positive non-small cell lung cancer (NSCLC) who had developed resistance to previous treatments.

Key findings for this difficult-to-treat population include:

• An objective response rate (ORR) of 45%.
• A disease control rate (DCR) of 88%.
• At a median follow-up of 6.9 months, 63% of patients remained on the treatment.

Significance for a High-Need Population

Ad

The trial results are particularly notable because there are currently no approved targeted therapies for patients with EGFR C797S-positive NSCLC. The study enrolled a heavily pretreated population, with 98% having previously received osimertinib and 53% having a history of brain metastases, underscoring the drug's potential in advanced cases.

BH-30643 also demonstrated a favorable safety profile across 174 patients treated at expansion doses. Treatment-related dose reductions and discontinuations were low, at 9% and 3% respectively. The most common adverse event was an elevation in bilirubin, which was reported as generally asymptomatic.

Market Impact and Next Steps

The positive data spurred immediate investor optimism, reflected in the premarket stock surge. BlossomHill's progress is further supported by a recent FDA Fast Track designation for BH-30643 in this specific patient group, which can expedite the development and review process.

Looking ahead, BlossomHill plans to initiate a global Phase 2 study for the drug in the first quarter of 2027. The successful advancement of BH-30643 could position the company as a leader in a niche but critical area of lung cancer treatment.